Today's Trend
Marker Therapeutics, Inc. (NASDAQ: MRKR) is moving higher as investors react to a wave of analyst updates that were mostly constructive on the company’s future earnings outlook. HC Wainwright reiterated its Buy rating and nudged several near- and medium-term EPS estimates higher, including Q1 2027, Q2 2027, Q3 2027, FY2026, FY2027 and FY2028. Brookline Capital Markets also raised estimates for FY2026 and FY2027, while maintaining very optimistic longer-term projections, despite trimming some individual quarter and outer-year forecasts. Separately, Zacks upgraded MRKR to Rank #2 (Buy), which adds to the bullish tone.
- HC Wainwright maintained a Buy rating and increased multiple earnings estimates for Marker Therapeutics, reinforcing a more favorable near- and medium-term outlook.
- Zacks upgraded Marker Therapeutics to Rank #2 (Buy), citing improved earnings prospects and signaling growing analyst optimism. Article Title
- Marker Therapeutics set the date for its 2026 annual meeting, a routine corporate update with limited immediate impact on the stock. Article Title
- Some Brookline Capital Markets estimates were cut for specific quarters and longer-term periods, including Q2 2026, Q3 2026, FY2028 and FY2029, which tempers the otherwise bullish analyst backdrop.